David Hsieh

1.3k total citations · 1 hit paper
37 papers, 1.1k citations indexed

About

David Hsieh is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, David Hsieh has authored 37 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 16 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in David Hsieh's work include Ubiquitin and proteasome pathways (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Glioma Diagnosis and Treatment (4 papers). David Hsieh is often cited by papers focused on Ubiquitin and proteasome pathways (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Glioma Diagnosis and Treatment (4 papers). David Hsieh collaborates with scholars based in United States, China and Taiwan. David Hsieh's co-authors include Jui‐Cheng Hsieh, G. Kerr Whitfield, Ichiro Kaneko, Mark R. Haussler, Carol A. Haussler, Peter W. Jurutka, Antony Hsieh, Liang You, David M. Jablons and Zhidong Xu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

David Hsieh

35 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Mechanisms of Vitamin D Action

2012 577 citations Mark R. Haussler, G. Kerr Whitfield et al. Calcified Tissue International profile →

Peers

David Hsieh

PFM

ONCOL

GENET

Roderick Bronson United States

Helena Olofsson Sweden

Gemma Ferrer‐Mayorga Spain

Yasuhiro Kawachi Japan

Andrzej Pławski Poland

Glendon M. Zinser United States

Yoshitaka Konda Japan

Gen Itoh Japan

Roderick Bronson United States

David Hsieh

475 ×1.1

PFM

467 ×1.1

175 ×0.8

ONCOL

154 ×1.0

324 ×2.7

GENET

Citations per year, relative to David Hsieh David Hsieh (= 1×) peers Roderick Bronson

Countries citing papers authored by David Hsieh

Since Specialization

Citations

This map shows the geographic impact of David Hsieh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hsieh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hsieh more than expected).

Fields of papers citing papers by David Hsieh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hsieh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hsieh. The network helps show where David Hsieh may publish in the future.

Co-authorship network of co-authors of David Hsieh

This figure shows the co-authorship network connecting the top 25 collaborators of David Hsieh. A scholar is included among the top collaborators of David Hsieh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hsieh. David Hsieh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kazmi, Syed Mohammad Ali, et al.. (2025). Phase II single-arm, single-center clinical trial of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer.. Journal of Clinical Oncology. 43(4_suppl). 1 indexed citations

Italiano, Antoine, Jonathan C. Trent, George W. Sledge, et al.. (2024). 75MO Atlas of tertiary lymphoid structures in solid tumors: Genomic features and prediction of response to immunotherapy. Annals of Oncology. 35. S244–S244. 1 indexed citations

Sahai, Vaibhav, Kent A. Griffith, David B. Zhen, et al.. (2024). Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).. Journal of Clinical Oncology. 42(16_suppl). 4116–4116. 2 indexed citations

Li, Daneng, Eric Xueyu Chen, David Hsieh, et al.. (2024). A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.. Journal of Clinical Oncology. 42(16_suppl). TPS4192–TPS4192. 3 indexed citations

Hsieh, David, Radhika Kainthla, Hao Zhu, & Muhammad Shaalan Beg. (2023). Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 41(4_suppl). 584–584. 3 indexed citations

Liu, Yang, Silvia Chang, David Hsieh, et al.. (2021). Generation of an HBV core phenotyping assay for evaluating HBV capsid compounds. Journal of Virological Methods. 292. 114117–114117. 2 indexed citations

Beg, Muhammad Shaalan, Hao Zhu, David Hsieh, et al.. (2020). A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab, in combination with pembrolizumab in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 38(4_suppl). TPS599–TPS599. 1 indexed citations

Kazmi, Syed Mohammad Ali, Nina N. Sanford, Todd A. Aguilera, et al.. (2020). Distinct clinical characteristics of young-onset pancreatic cancer patients.. Journal of Clinical Oncology. 38(4_suppl). 674–674. 1 indexed citations

Whitfield, G. Kerr, et al.. (2018). Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma. Journal of Cellular Biochemistry. 120(1). 533–543. 4 indexed citations

10.

Camus, Grégory, Byoung Geun Han, Tarik Asselah, et al.. (2017). Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. Journal of Viral Hepatitis. 25(2). 134–143. 18 indexed citations

11.

Whitfield, G. Kerr, et al.. (2017). Human Hairless Protein Roles in Skin/Hair and Emerging Connections to Brain and Other Cancers. Journal of Cellular Biochemistry. 119(1). 69–80. 10 indexed citations

12.

Yang, Yi‐Lin, Jian Ni, Ping‐Chih Hsu, et al.. (2015). Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine. 19(10). 2385–2396. 9 indexed citations

13.

Zhang, Shulin, Yi‐Lin Yang, Yucheng Wang, et al.. (2014). CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. Journal of Experimental & Clinical Cancer Research. 33(1). 93–93. 24 indexed citations

14.

Hung, Ming‐Szu, Zhidong Xu, Yu Chen, et al.. (2013). Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. International Journal of Oncology. 43(5). 1517–1522. 18 indexed citations

15.

Liu, Shu, David Hsieh, Yi‐Lin Yang, et al.. (2013). Coumestrol from the national cancer Institute’s natural product library is a novel inhibitor of protein kinase CK2. BMC Pharmacology and Toxicology. 14(1). 36–36. 47 indexed citations

16.

Haussler, Mark R., G. Kerr Whitfield, Ichiro Kaneko, et al.. (2012). Molecular Mechanisms of Vitamin D Action. Calcified Tissue International. 92(2). 77–98. 577 indexed citations breakdown →

17.

Hsieh, David. (2011). Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas. Current Pharmaceutical Design. 17(23). 2370–2385. 1 indexed citations

18.

Lim, Seung‐Oe, et al.. (2011). Notch1 binds and induces degradation of Snail in hepatocellular carcinoma. BMC Biology. 9(1). 83–83. 33 indexed citations

19.

Hsieh, David, et al.. (2010). IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochemical and Biophysical Research Communications. 397(2). 367–372. 53 indexed citations

20.

Hsieh, Antony, et al.. (2010). Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. Journal of Cellular Physiology. 226(4). 1118–1127. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact